<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199979</url>
  </required_header>
  <id_info>
    <org_study_id>DAUFIN</org_study_id>
    <nct_id>NCT00199979</nct_id>
  </id_info>
  <brief_title>Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients</brief_title>
  <official_title>Multicenter, Randomized, Open-Label Trial, Assessing the Efficacy of Zidovudine, Lamivudine and Nevirapine Combination Administered Twice Daily, Versus the Association of Tenofovir, Lamivudine and Nevirapine, Once Daily, in Antiretroviral Naive HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDEX</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDEX</source>
  <brief_summary>
    <textblock>
      The study will compare the immuno-virological efficacy, and safety, of a once daily
      antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily
      association (fixed dose combination of zidovudine/lamivudine + nevirapine) in ARV-Naive HIV-1
      infected subjects, with CD4 cell count below 350/µL or below 15%, whatever the viral load.
      Pharmacological (nevirapine concentrations) and virologic data (resistance mutations in case
      of failure) will also be provided, as well as adherence rate and quality of life in respect
      of the treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      96-week antiviral efficacy of tenofovir + lamivudine + nevirapine, once daily, versus a
      reference antiretroviral treatment given twice daily (zidovudine/lamivudine + nevirapine)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date>June 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the antiviral efficacy of AZT, 3TC, and NVP combination, in two doses per day, to the association of TDF, 3TC, and NVP, once a day, in antiretroviral naive HIV-1-infected patients (plasma viral load below 400 copies/ml at 96 weeks).</measure>
  </primary_outcome>
  <enrollment>250</enrollment>
  <condition>Hiv Infection With Antiretroviral Therapy Indication</condition>
  <condition>CD4 Below 350/µL or Below 15%</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, confirmed by a western-blot assay, at least 6 months after primary
             infection

          -  Age &gt; or equal to 18 years of age

          -  No prior antiretroviral treatment

          -  Karnofsky superior to 60%

          -  CD4 T cells &lt; 350/µL (2 measures, with at least a 1-month interval) in women, study
             will be proposed when CD4 cell count is below 250/µL, as nevirapine liver toxicity
             increases (X10) when CD4 are &gt; 250/µL

          -  Written informed consent

        Exclusion Criteria:

          -  HIV-2 infection or co-infection

          -  Prior antiretroviral treatment

          -  Intolerance, or contraindication to investigational drugs

          -  Pregnant or breast-feeding woman, or plan to become pregnant

          -  Active untreated opportunistic infections (AIDS-defining illness, category C, CDC,
             1993), or malignancies requiring cytotoxic chemotherapy

          -  Biological criteria: hemoglobin &lt; 10 G/DL, neutrophil count &lt; 1000/µL, platelets &lt;
             50000/µL, creatinine &gt; 2N, ASAT or ALAT &gt; 2.5N, bilirubin &gt; 2N, hypophosphatemia

          -  Prevision of poor adherence

          -  HBC co-infection (Ag Hbs positive) or HVC co-infection (positive HCV PCR)

          -  Liver failure, alcohol abuse

          -  Treatment administration not recommended with investigational drugs

          -  Interferon, interleukin, or HIV vaccine treatment

          -  Informed consent not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>REY MR DAVID, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CISIH CHRU STRASBOURG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>REY DAVID, M.D</last_name>
    <phone>0388116451</phone>
    <phone_ext>33</phone_ext>
    <email>david.rey@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LARGUIER JEAN-SYLVAIN, M.D</last_name>
    <phone>0437451717</phone>
    <phone_ext>33</phone_ext>
    <email>daufin@rcts.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cisih, Clinique Medical A, Hopitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>REY DAVID, M.D</last_name>
      <phone>0388116333</phone>
      <phone_ext>33</phone_ext>
      <email>david.rey@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>REY DAVID, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 15, 2005</last_update_submitted>
  <last_update_submitted_qc>December 15, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2005</last_update_posted>
  <keyword>Antiretroviral Therapy</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>HIV Viral Load</keyword>
  <keyword>Adherence</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Resistance Mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

